How do I buy Krystal Biotech, Inc. Common Stock (KRYS) stock?

Buying Krystal Biotech, Inc. Common Stock (KRYS) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "KRYS", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy KRYS by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for KRYS on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Krystal Biotech, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Krystal Biotech, Inc. Common Stock (KRYS) pay dividends?

At the moment, Krystal Biotech, Inc. Common Stock (KRYS) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track KRYS's performance via the price chart in the Gotrade app.

Is buying KRYS on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy KRYS?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if KRYS is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Krystal Biotech, Inc. Common Stock (KRYS) Stock Price: Nov 11 Close $308.81

Latest news

Zacks Investment Research

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

NegativeKRYSOctober 26, 2026

Zacks Investment ResearchNegative

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

News tone: automated (AI) classification of the article's content, not a price prediction.

About Krystal Biotech, Inc. Common Stock

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

SectorHealthcare

IndustryBiotechnology

Employees295

CEOMr. Krish S. Krishnan M.B.A., M.S.

IPO DateSep 20, 2017

HeadquartersPittsburgh, PA

Key Executives

Name	Title	Year Born
Mr. Krish S. Krishnan M.B.A., M.S.	Founder, Chairman, President & CEO	1965
Ms. Suma M. Krishnan	Founder, President of R&D and Director	1965
Ms. Kathryn A. Romano CPA	Executive VP & Chief Accounting Officer	1982
Mr. John C. Thomas	EVP, General Counsel & Corporate Secretary	1974
Mr. John Karakkal	Vice President of North American Sales & Marketing	—
Dr. Stephane Paquette Ph.D.	Senior Vice President of Corporate Development	—
Mr. Josh Suskin	Senior Director & Head of US Human Resources	—
Mr. Laurent Goux	Executive VP & Head of International	1975
Dr. David Chien M.D.	Senior Vice President of Clinical Development	—
Ms. Christine Wilson	Senior VP & Head of US Commercial	—

Fundamentals

Valuation

Price-to-sales ratio31.26

Price-to-book value6.33

Profitability

Return on Equity19.00%

Return on Assets18.00%

Return on Sales51.00%

Gross margin (latest quarter)94.07%

EBITDA$233.28M

Trading

Average volume323,654

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 44.96
MACD 12/26/9: -6.91
EMA 9 of MACD: -6.65
MACD histogram: -0.26
SMA 50: $329.36; Price below SMA 50
EMA 50: $323.82; Price below EMA 50
SMA 200: $309.41; Price below SMA 200
EMA 200: $303.35; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

6 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $361.00
Average: $394.83
High: $441.00

Goldman Sachs

Andrea Newkirk

Buy

Target price

$441.00

Citigroup

Yigal Nochomovitz

Buy

Target price

$412.00

HC Wainwright & Co.

Joseph Pantginis

Buy

Target price

$361.00

RBC Capital

Lisa Walter

Buy

Target price

$375.00

B of A Securities

Alec Stranahan

Buy

Target price

$400.00

TD Cowen

Ritu Baral

Buy

Target price

$380.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026							+0.6	+15.0	-8.6	+2.1	+4.4

Earnings per share

$7.66

-

Krystal Biotech, Inc. Common Stock (KRYS) Stock

Key stats

Compare with KRYS

Recent news

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech Q3 Earnings Call Highlights

Krystal Biotech Q3 Earnings Call Highlights

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech Q3 Earnings Call Highlights

Krystal Biotech Q3 Earnings Call Highlights

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

About Krystal Biotech, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade